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ABSTRACT 
Cardioprotective Effects of Mitochondrial-Targeted Antioxidants  
in Myocardial Ischemia/Reperfusion (I/R) Injury 
Reactive oxygen species (ROS) generated during myocardial I/R contribute to 
post-reperfused cardiac contractile dysfunction. Damaged cardiomyocyte 
mitochondria are major sites of excess ROS generation during reperfusion. 
We hypothesized that reducing mitochondrial ROS formation should attenuate 
myocardial I/R injury and thereby improve function of isolated perfused rat 
hearts subjected to I(30min)/R(45min) compared to untreated I/R hearts. 
Mitoquinone (MitoQ, MW=579g/mol; complexed with cyclodextrin 
(MW=1135g/mol) to improve water solubility, total MW=1714g/mol), a 
coenzyme Q derivative, and SS-31 (Szeto-Schiller) peptide ((D-Arg)-Dmt-Lys-
Phe-Amide, MW=639g/mol, Genemed Synthesis, Inc., San Antonio, TX), an 
alternating cationic-aromatic peptide, are selective mitochondrial ROS 
inhibitors which significantly improved post-reperfused cardiac function 
compared to untreated I/R controls in this study (p<0.05). MitoQ elicits 
antioxidant effects through the recycling of ubiquinone to ubiquinol, whereas 
SS-31 utilizes an antioxidant dimethyltyrosine residue. Improvement in post-
reperfused cardiac function by MitoQ or SS-31 was associated with a 
significant decrease in myocardial tissue infarct size compared to untreated 
I/R hearts (p<0.01). These results suggest mitochondrial-derived ROS are 
important contributors to I/R injury, and MitoQ or SS-31 when administered at 
reperfusion may potentially augment the benefits of angioplasty or 
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thrombolytic treatment in the clinical setting for myocardial infarction, where 
pretreatment may not be a practical option. 
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INTRODUCTION 
The Clinical Setting of Myocardial I/R 
Ischemic heart disease is the leading cause of morbidity and mortality in 
the industrialized world and also is the leading cause of mortality in the United 
States, accounting for nearly 20% of all deaths in the United States(1-5). Acute 
myocardial infarction can progress into persisting conditions of morbidity, such as 
heart failure(5, 6). During myocardial ischemia the coronary blood flow is 
interrupted, depriving cardiomyocytes of oxygen (O2), glucose, and fatty acids. 
Ischemia lasting for 30 minutes or longer will result in irreversible cardiac 
damage(7). Quickly restoring blood flow (i.e., reperfusion) following ischemia is 
critical in salvaging heart tissue. Surgical interventions, such as coronary 
angioplasty or emergency coronary artery bypass grafting, as well as 
thrombolytic drug treatments can enable restoration of coronary blood flow to 
reduce the amount of irreversible tissue damage that occurs in the myocardium 
during periods of prolonged ischemia(5, 8). However, as coronary blood flow is 
reestablished, ischemic damage is exacerbated by a burst of reactive oxygen 
species (ROS) generated within seconds of reperfusion(8, 9). Increased 
oxidative stress during reperfusion contributes to the death of cardiomyocytes 
that were viable before reperfusion occurred(10, 11). It has been suggested that 
up to 50% of myocardial infarct size is due to reperfusion injury occurring after 
ischemia, and the prognosis for patients surviving an acute myocardial infarction 
is dependent on infarct size(5, 10). Clinical treatment of I/R injury remains a 
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challenge as no approved pharmaceutical agents effectively limit I/R-induced 
damage(4, 12).  
The Need for Preclinical Investigation of Myocardial I/R 
Jennings et al. first described the concept of myocardial I/R injury in 1960 
using a canine I/R model, which resulted in cell swelling, myofibril contracture, 
sarcolemma disruption, and calcium phosphate accumulation within 
mitochondria(13). Treatment of myocardial I/R injury remains to be a challenge 
because reperfusion itself is associated with ventricular arrhythmias, stunning 
(i.e., contractile dysfunction of viable cells), and coronary vascular dysfunction(8, 
10). Identifying the specific mechanisms by which myocardial I/R injury occurs 
will allow for the development of efficient treatment strategies to reduce I/R injury 
in myocardial infarction or heart transplantation patients and further prevent 
ischemic heart failure. Effective cardioprotective treatment should reduce both 
the amount of tissue infarction and viable cell dysfunction.  
Implications of Mitochondria in Myocardial I/R 
Ischemia has a direct effect on adenosine triphosphate (ATP) production. 
As previously mentioned, ischemia prevents cardiomyocytes from receiving O2, 
glucose, and fatty acids and also reduces the amount of adenine nucleotides and 
cytochrome c available in mitochondria. Since mitochondria consume 85 to 90% 
of the O2 in a cell to synthesize ATP from adenosine diphosphate (ADP) and 
inorganic phosphate (Pi) during oxidative phosphorylation, the function of 
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mitochondria is quickly disrupted by ischemia. Under normal conditions, 
mitochondria produce over 90% of cellular energy in the form of ATP. Ischemic 
conditions disrupt ATP production, leading to an overproduction of ROS at 
reperfusion with the reestablishment of O2 supplied by coronary blood vessels. 
Mitochondria are implicated in I/R as a major source of ROS(14-20). Excess 
ROS leads to mitochondrial and cardiac contractile dysfunction, which can result 
in cell damage and additional tissue death, contributing to I/R injury.  
Mitochondria, Both a Source and a Target for ROS 
Mitochondria are extremely susceptible to oxidative damage since a large 
amount of ROS is generated within the mitochondria during I/R(14-18, 20). An 
excess of ROS leads to mitochondrial dysfunction, which is an important factor in 
the development of cardiac hypertrophy, contractile dysfunction, and subsequent 
heart failure(1, 6, 21). This sequence of events could lead to a decreased ability 
to recover from myocardial I/R and reduce the quality of life in patients following 
myocardial I/R. In dysfunctional myocardium, there is a significant increase in 
ROS production(1, 21, 22). Increased ROS production in dysfunctional 
mitochondria induces further ROS production resulting in a feed forward-loop of 
ROS elevation(14, 18). Dysfunctional mitochondria are associated with increased 
ROS production and oxidative mitochondrial DNA damage due to their inability to 
produce energy through the electron transport chain (ETC) complexes(6, 12, 21).  
Since mitochondrial DNA is situated closer to the primary site of ROS generation 
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and lacks both protective histones and efficient DNA repair mechanisms, it can 
easily become mutated and potentially lead to cardiomyopathy(14, 18, 23, 24).  
Sequence of ROS-Mediated I/R Damage: 
The Mitochondrial Respiratory Chain Releases ROS 
Oxidative phosphorylation is inactivated by ischemia, which results in an 
accumulation of phosphate, fatty acids, lactic acid, and cellular calcium while 
decreasing cellular pH and the amount of adenine nucleotides and cytochrome c 
available in the mitochondria(10, 12, 25, 26). The rapid restoration of the 
decreased pH upon reperfusion, possibly involving the opening of the 
mitochondrial permeability transition pore complex (MPTP), is a contributing 
factor to I/R injury. Reoxygenation with an acidic buffer inhibits opening of the 
MPTP(10, 27). At the time of reperfusion, a burst of ROS including superoxide 
(SO), hydrogen peroxide (H2O2), and peroxynitrite are generated by the 
interaction of O2 with the damaged mitochondrial respiratory chain, primarily 
through the uncoupling of complexes I and III(12, 28, 29). It is suggested that a 
large portion of ROS in the I/R heart is a result of the uncoupling of complexes I 
and III in the mitochondrial ETC(28). Under physiological conditions O2 is the 
final electron acceptor, accepting four electrons from complex IV, and is used to 
produce water (H2O), a by-product of respiration(14, 18)(Figure 1). 
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Figure 1. Electron transport 
chain (ETC) function in 
physiological conditions. 
Maintanence of the 
electrochemical gradient of 
the mitochondrial 
membranes by the ETC is 
essential for ATP production. 
In these conditions, oxygen 
(O2) accepts four electrons 
from complex IV. Adapted 
from Szeto 2006.  
 
However, in dysfunctional mitochondria, electrons leaking from complexes I and 
III are accepted by O2 to generate SO, a form of ROS(14, 18, 30)(Figure 2). 
Figure 2. Electron transport 
chain (ETC) function at 
reperfusion. Oxygen (O2) 
generates superoxide (O2-) by 
accepting electrons leaking from 
complexes I and III. Even though 
O2- cannot diffuse across 
membranes, O2- is generated in 
both the intermembrane space 
and within the matrix by this 
mechanism. Forms of superoxide 
dismutase can quickly convert 
O2- to hydrogen peroxide (H2O2), 
which is more stable and able to 
diffuse into the cytosol. Adapted 
from Szeto 2006 and modified.  
 
Excessive amounts of ROS produced during myocardial I/R overwhelm the 
physiological antioxidant mechanisms of glutathione, glutathione peroxidase, 
thioredoxin, glutaredoxina-tocopherol, ubiquinol, ascorbic acid, superoxide 
dismutase, and catalase(14, 18, 21, 26). The release of excess ROS damages 
cells directly. As a signaling molecule, ROS can activate hypertrophy and 
apoptosis pathways(21, 31-33). ROS directly damages nucleic acids, proteins, 
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and lipids, consequently disrupting membrane integrity and cell function as a 
result(14, 18, 21, 26, 30). SO can quickly be converted into H2O2, which is more 
stable, has a longer half-life, and can diffuse across the mitochondrial 
membranes into the cytosol(14, 32, 34). Conversion of H2O2 into hydroxyl 
radicals or carbonate anions, which are both highly reactive forms of ROS, can 
further promote oxidative stress(14). Adult rat cardiomyocytes treated with H2O2 
showed that H2O2 concentration-dependently activates four kinase signaling 
pathways (i.e., ERK1/2, p38 kinase, JNK, and Akt) involved in the regulation of 
cardiomyocyte hypertrophy and/or apoptosis. Lower H2O2 concentrations 
resulted in hypertrophy, while higher H2O2 concentrations induced apoptosis(31, 
35, 36). Varying levels of oxidative stress induced in neonatal rat ventricular 
myocytes also showed the same concentration-dependent effect of ROS on 
cardiac hypertrophy and apoptosis(32, 37-40). Nitric oxide (NO) can interact with 
SO to form peroxynitrite, a highly reactive form of ROS(30, 41). Peroxynitrite can 
rapidly modify proteins, DNA, and membranes to cause oxidative damage(10, 
21, 30, 42) and irreversibly inhibit cellular respiration(43). 
Sequence of ROS-Mediated I/R Damage:  
NADPH Oxidase, Another Important ROS Source 
Another source of ROS that originates in the mitochondria of 
cardiomyocytes and endothelial cells is nicotinamide adenine dinucleotide 
phosphate oxidase (Nox)(10, 22, 44-48). Nox4, for example, is primarily localized 
in mitochondria and exhibits increased ROS producing activity in dysfunctional 
cardiomyocytes(22, 44-48). Genetic deletion of p47phox, the cytosolic component 
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of Nox, has confirmed the implication of Nox in ROS-induced cardiac dysfunction 
in a mouse myocardial infarction model. Analysis 30 days following myocardial 
infarction showed that there was a reduction in left ventricular remodeling, 
dysfunction, and dilation which paralleled the decrease in cardiomyocyte 
apoptosis, hypertrophy, and intersititial fibrosis at the same time point. These 
results also suggest that Nox may be involved in the development of heart failure 
following myocardial infarction(6, 28, 48). However, it has been suggested that 
Nox4, which is primarily localized in mitochondria, does not require p47phox, 
p67phox, or Rac for activation but is dependent on SO levels for its expression. 
At both cardiac cellular and tissue levels, the overexpression of Nox4 has been 
shown to increase SO generation in mitochondria and contribute to cardiac 
dysfunction, fibrosis, apoptosis, and mitochondrial dysfunction(49). 
Sequence of ROS-Mediated I/R Damage:  
ROS-induced eNOS Uncoupling 
The production of ROS during reperfusion from mitochondria and Nox can 
stimulate further increases in ROS formation as a feed-forward loop. ROS from 
these sources may oxidize tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) 
and consequently promote eNOS uncoupling, which leads to additional ROS 
production(29, 50). When using BH2 as a co-factor, endothelial nitric oxide 
synthase (eNOS) is considered uncoupled and produces SO instead of NO. The 
release of SO from uncoupled eNOS causes oxidative damage and increases 
production of other forms of ROS(51). A schematic diagram of the implications of 
uncoupled eNOS in continuing the feed-forward loop of excessive ROS 
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production in I/R is shown in Figure 3. This diagram focuses on protein kinase C 
(PKC)-mediated ROS generation in I/R as an example, though other pathways 
contributing to the feed-forward loop of ROS overproduction in I/R exist.  
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic diagram of protein kinase C (PKC)-mediated ROS overproduction 
in ischemia/reperfusion (I/R). The insult caused by I/R stimulates the release of 
cytokines, which activate cytokine receptors. These cytokine receptors in turn generate 
diacylglycerol (DAG), a second messenger signaling lipid which activates PKC. PKC 
phosphorylates p47phox, an essential component in NADPH oxidase (Nox) activity, to 
activate Nox, resulting in SO (O2-) release. Phosphorylation by PKC can also directly 
promote O2- release from mitochondria and uncoupled eNOS. All of these sources of 
excess O2- contribute to the oxidation of BH4 to BH2, which promotes further eNOS 
uncoupling, resulting in a feed-forward loop of ROS overproduction during I/R. Adapted 
and modified from Schmidt and Alp 2007. 
 
It has previously been shown that eNOS uncoupling is a major source of 
ROS in a hind limb I/R model and contributes to post-reperfused cardiac 
contractile dysfunction in myocardial I/R(52). The uncoupling of eNOS can 
quickly cause endothelial dysfunction within the first 5-10 min of reperfusion(52, 
53). Hemodynamic stress is also known to lead to eNOS uncoupling. However, 
supplementation with BH4 in mice with heart disease following pressure overload 
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prevents eNOS uncoupling and reduces left ventricular hypertrophy, cardiac 
dysfunction, and fibrosis (54). Folic acid also restores reduced BH4 production, 
which increases coupled eNOS activity to protect the heart. Folic acid preserves 
cardiac function in I/R rats, suggesting that there is a cardioprotective effect in 
decreasing ROS production by increasing available BH4 to increase coupled 
eNOS activity in I/R(55). Coupled eNOS produces NO. 
Once NO is released it acts as a diffusable signaling molecule and 
regulates blood pressure by increasing the production of cyclic guanosine 
monophospate (cGMP) to relax smooth muscle(1). Previous studies have shown 
that the pathway between eNOS, NO, and cGMP is an essential activator of 
mitochondrial biogenesis(56, 57). Mitochondrial biogenesis increases energy 
production and has a cardioprotective function in studies using rats, dogs, and 
humans(58-62). NO is able to improve coronary blood flow, inhibit accumulation 
of neutrophils, and inactivate SO radicals(10, 43, 63). The importance of these 
effects of NO were demonstrated by systemically inhibiting NO synthesis in vivo, 
resulting in peripheral vasoconstriction and hypertension, which induce 
cardiovascular reflexes that change preload, afterload, and heart rate(43, 64, 65). 
Additionally, it has been shown that NO regulates cellular respiration in the 
myocardium by increasing the efficiency of O2 consumption in oxidative 
phosphorylation.  Inhibiting NO sythesis at all levels of cardiac contractile 
performance significantly increased O2 consumption with no effect on the rate of 
ATP synthesis or amount of ATP produced, suggesting that the effect of 
inhibition of NO synthesis is unrelated to contractile performance. It has therefore 
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been suggested that endogenous NO enhances the coupling of O2 consumption 
to both ATP synthesis and cardiac performance(43). Despite its cardioprotective 
effects, NO is also known to reversibly bind to cytochrome c to inhibit energy 
production in the mitochondria and produce ROS and reactive nitrogen species 
by displacing O2(66). NO can react with SO to generate peroxynitrite, a highly 
reactive form of ROS(30, 42). NO is also able to induce apoptosis by activating 
the opening of the MPTP(41). It has been demonstrated that at pathological 
concentrations, NO activity switches from an anti-apoptotic effect to a pro-
apoptotic effect(67, 68) Endothelial dysfunction is a key event to induce 
leukocyte mediated inflammation leading to contractile dysfunction in the 
myocardium(52, 53). This sequence of events contributes to I/R injury. However, 
initiating sources of ROS that induce eNOS uncoupling are not well defined. 
Investigating the initiating sources of ROS and ways to inhibit excess ROS 
production in I/R is therefore of great significance. 
Sequence of ROS-Mediated I/R Damage:  
Lipid Peroxidation and Mitochondrial Permeability 
As mentioned before, excess release of ROS leads to an increased 
production of ROS. Lipid peroxidation can occur as a result of ROS release 
during I/R and cause membrane damage, such as loss of membrane potential. 
Lipid peroxidation can damage the sarcolemmal membrane and cause an 
increase of intracellular calcium that overwhelms the physiological calcium 
regulation mechanisms(10-12, 26). Excessive increases in intracellular calcium 
leads to cardiac hypertrophy, fibrosis, opening of the MPTP, contractile 
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dysfunction, cell death, and potentially heart failure(10, 11, 69). The opening of 
the MPTP induces cell death by the irreversible loss of the mitochondrial 
electrochemical membrane, causing mitochondrial swelling and rupture. 
Cytochrome c release from the MPTP into the cytosol inhibits electron transport 
and activates caspase mediated apoptosis cascades(12, 69, 70). Linoleic and 
arachidonic acid, for example, are unsaturated fatty acids that create 4-
hydroxynonenal (HNE) as a by-product of their peroxidation. HNE can create 
protein adducts and cause additional lipid peroxidation. HNE also induces 
formation of mitochondrial membrane permeabilization (MMP) and subsequent 
apoptosis. NO, peroxynitrite, and HNE can each independently cause lipid 
peroxidation and MMP. It is suggested that this effect is mediated by MPTP since 
the opening of the pore by this mechanism is inhibited by cyclosporin A, a direct 
inhibiter of the MPTP(71). Cyclosporin A binds to cyclophilin D and detaches 
cyclophilin D from the inner mitochondrial membrane(72) (Figure 4). The MPTP 
is a channel made up of proteins that form a complex to span the inner and outer 
mitochondrial membranes. The adenine nucleotide translocator, cyclophilin D, 
and the voltage-dependent anion channel are the key functional MPTP 
constituents(18, 72)(Figure 4).  
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Figure 4. The mitochondrial 
transition pore (MPTP) spans the 
outer and inner mitochondrial 
membranes. The peripheral 
benzodiazepine receptor (IBP), 
hexokinase (HK), adenine 
nucleotide translocase (ANT), 
creatine kinase (CK, in muscle 
mitochondria) and cyclophilin D 
(CpD) are the basic subunits of 
the MPTP. When cyclosporin A 
(CsA) binds (⊕) to CpD, CpD is 
unable to associate with the 
MPTP, preventing the MPTP 
from opening. Adapted and 
modified from Szewczyk and 
Wojtzak 2002. 
 
Although the mechanism by which NO, peroxynitrite, and HNE initiate MMP has 
not been clearly defined, the adenine nucleotide translocator component of the 
MPTP responds to these forms of ROS by opening the MPTP to increase MMP. 
MMP can affect both the outer and inner mitochondrial membranes 
simultaneously, or each individually. The opening of the MPTP uncouples 
oxidative phosphorylation, reducing the amount of ATP available, and allows the 
release of compounds normally sequestered by either or both of the 
mitochondrial membranes(10, 42, 69). Both of these effects can result in cell 
death. For example, prolonged MPTP opening can cause a loss of 
electrochemical membrane potential and release cytochrome c, Smac/DIABLO, 
and apoptosis-inducing factor (AIF) from the intermembrane space to activate 
apoptosis pathways, including those mediated by caspase activity(26, 41)(Figure 
5).  
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Figure 5. The mitochondrial 
transition pore (MPTP) in 
apoptosis pathways. ROS, 
DNA damage, and other 
apoptosis-inducing signals 
promote the binding of Bax, a 
proapoptotic protein, with the 
outer mitochondrial membrane 
near the MPTP. Bax activity 
promotes the opening of the 
MPTP, which releases 
cytochrome c and apoptosis-
inducing factor (AIF) into the 
cytosol. Elevated calcium and 
ROS can also directly stimulate 
MPTP opening. The release of 
cytochrome c and AIF into the 
cytosol activates caspase-
mediated apoptosis pathways. 
Adapted from Szewczyk and 
Wojtzak 2002 and modified. 
 
 
Mitochondria as a Potential Therapeutic Target in I/R 
Although mitochondrial-targeted antioxidant pretreatment can effectively 
limit I/R injury, pretreatment is not always possible in cases of myocardial 
infarction(5, 15, 16, 73, 74). Therefore, evaluating the cardioprotective efficacy of 
mitochondrial-targeted antioxidants when given at reperfusion is of high 
significance. Previous studies have shown that selective mitochondrial 
antioxidants administered before ischemia and at reperfusion can reduce heart, 
liver, and kidney damage beginning immediately following ischemia, thus 
suggesting that selective mitochondrial antioxidants can work quickly in 
attenuating I/R injury(18, 30, 75). If these agents can work expeditiously and 
effectively when administered at the time of coronary blood flow restoration, 
mitochondrial-targeted antioxidants may be a practical option in the clinical 
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setting in cases of myocardial infarction. Following myocardial I/R, treatments 
that can attenuate endothelial and cardiac contractile dysfunction will limit tissue 
damage and allow these patients to have a better quality of life.   
Mitoquinone, a Mitochondrial-Targeted Antioxidant 
Conventional antioxidants, such as coenzyme Q, vitamin E, and N-
acetylcysteine, have limited efficacy in protecting mitochondria from oxidative 
damage because they are not targeted selectively to the mitochondria, where 
most I/R damage occurs(14-18, 26). Therefore, selectively targeting mitochondria 
with antioxidants may be an effective strategy to attenuate release of 
mitochondrial ROS (Figure 6). 
Figure 6. Reduction of mitochondrial 
reactive oxygen species (ROS) limits 
excess cell death. Mitochondrial 
ROS stimulate ROS production 
outside mitochondria, increasing 
oxidative stress and apoptosis 
signaling cascade activation. ETC 
complexes and Nox4 are major ROS 
sources in dysfunctional 
mitochondria. Specific mitochondrial-
targeted antioxidants exert 
cardioprotective effects. Adapted 
from Bayeva  et al. 2013 and 
modified. 
 
Attachment of an antioxidant to a lipophilic cation allows the antioxidant to 
concentrate 100 to 1000-fold within mitochondria(14, 17, 76). Mitoquinone 
(MitoQ, MW=579g/mol; the MitoQ referred to in this study was complexed with 
cyclodextrin (MW=1135g/mol) to improve water solubility, total MW=1714g/mol), 
a coenzyme Q analog, incorporates a lipophilic triphenylphosphonium (TPP) 
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cation, which easily passes through phospholipid bilayers and is driven by the 
large electrochemical mitochondrial membrane potential (150-180 mV), to 
concentrate MitoQ specifically within the mitochondria at a several hundred-fold 
concentration(16-18, 76). The TPP cation is covalently attached to an ubiquinol 
antioxidant to scavenge ROS and prevent lipid peroxidation(1, 16, 17, 76, 77). 
After entering the mitochondria, the respiratory chain reduces MitoQ to its active 
ubiquinol form. A previous study has shown that accumulation of ubiquinol within 
mitochondria is necessary for the efficacy of MitoQ in limiting myocardial I/R 
injury since quinol by itself is unable to cross the mitochondrial membrane(16). 
The oxidation of MitoQ into its quinone form scavenges ROS inside 
mitochondria; complex II of the respiratory chain then recycles MitoQ back into its 
active quinol form continuously after each time MitoQ completes antioxidant 
activity(16, 17, 78). Another aspect of MitoQ that could make it an attractive 
therapeutic tool is that no significant adverse effects have been reported after 
long-term administration. MitoQ does not act as a pro-oxidant in wild-type mice in 
vivo(17). No significant adverse effects were reported when MitoQ was 
administered as an oral tablet to patients for up to a year, however there was 
mild nausea and vomiting reported in the MitoQ treatment groups(76, 79). In one 
study, administration of MitoQ (500 µM in drinking water) to mice for 20-28 weeks 
allowed MitoQ to accumulate primarily in the liver and heart but also slightly in 
the brain. Long term MitoQ administration did not increase mitochondrial 
oxidative stress in vivo, suggesting that MitoQ does not have pro-oxidant effects 
when administered over an extended period of time. Additionally, mitochondrial 
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enzyme activity was not negatively affected. MitoQ seemed to reduce plasma 
levels of triglyceride but did not alter glucose, insulin, free fatty acid, or 
cholesterol levels in plasma. Additionally, these MitoQ treated mouse heart and 
liver tissues did not have any significant differences in their gene expression 
profile compared to untreated controls(17). In human studies where MitoQ was 
administered orally as a daily dose for up to one year, no severe side effects 
were reported(76, 79). Another aspect of TPP conjugated antioxidants is that 
uptake is reversible; they can be rapidly cleared from any organ of the body once 
administration is stopped(80). 
SS-31, Also a Mitochondrial-Targeted Antioxidant 
The SS-31 (Szeto-Schiller) peptide ((D-Arg)-Dmt-Lys-Phe-Amide, 
MW=639 g/mol, Genemed Synthesis, Inc., San Antonio, TX) is also of interest in 
further understanding the role of mitochondrial derived ROS and efficacy of 
inhibiting mitochondrial ROS production in myocardial I/R. SS-31 is a cell-
permeable peptide, specifically targeted to inner mitochondrial membranes 
based on its alternating aromatic residues and basic amino acid sequence, with 
an antioxidant dimethyltyrosine moiety (Dmt)(14, 26). Tyrosine scavenges ROS 
to form unreactive compounds, attributing the ability of SS-31 to scavenge ROS 
to the Dmt amino acid residue, which has been found to be more effective than 
tyrosine(18, 81, 82). The backbones of most peptides have a tendency to form 
hydrogen bonds with water, making these peptides not cell-permeable. However, 
the alternating aromatic-cationic motif of SS-31 allows it to rapidly diffuse through 
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cell membranes(18). Unlike TPP-conjugated antioxidants, SS-31 does not rely on 
the electrochemical mitochondrial membrane potential to selectively accumulate 
10,000-fold inside mitochondria(14, 18). In dysfunctional mitochondria, the 
electrochemical membrane potential may be disrupted(18, 73). Therefore, the 
ability to target an antioxidant selectively to mitochondria independent of 
membrane potential may prove useful in I/R. Additionally, high doses of lipophilic 
cation attached antioxidants may depolarize the mitochondrial membrane 
potential, but SS-31 at concentrations as high as 1 mM did not depolarize the 
mitochondrial membrane potential(14, 18, 26). SS-31 can cross plasma 
membranes in both directions in an energy-independent manner(14, 26, 83). In 
liver and brain mitochondria, SS-31 reached its maximum intracellular 
concentration within 2 min of incubation(26). SS-31 achieved steady state by 30 
minutes of incubation with neuronal cell lines(26). SS peptides have relatively 
long elimination half-lives and are also small, water soluble, stable and resistant 
to peptidase degradation(14, 26). When SS-31 was incubated in mouse, rat, dog, 
monkey and human plasma at 37 oC for 1 hour there was little degradation. SS-
31 was most stable in human plasma, with a half-life of about 30 hours, and was 
classified as a low clearance compound in human liver microsomes(12, 84). 
Previous studies have shown that in ex vivo and in vivo I/R models, SS peptides 
scavenge H2O2, hydroxyl radicals, and peroxynitrite while also inhibiting lipid 
peroxidation. Consequently, there is less cytochrome c release and subsequent 
oxidant-induced cell death because the opening of the MPTP is inhibited(12, 14, 
18, 26, 73, 85). Since SS-31 reduced infarct size and tissue dysfunction in I/R 
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models as a pretreatment, it is possible that SS-31 would have a similar effect 
when administered at reperfusion(86). One limitation of previous studies is that 
they did not measure both cardiac function and infarct size in the same animals 
that were administered SS-31 exclusively at the time of reperfusion.  
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HYPOTHESIS 
It has previously been determined that the formation of ROS within the 
mitochondria under I/R conditions is a major contributor to I/R injury(14-16). It is 
hypothesized that antioxidants specifically targeted to the mitochondria to 
attenuate ROS formation will reduce I/R injury by limiting cardiac contractile 
dysfunction and cardiac tissue damage. MitoQ, a coenzyme Q derivative, and 
SS-31, an alternating cationic-aromatic peptide, are selective mitochondrial ROS 
inhibitors. MitoQ incorporates a lipophilic TPP cation covalently attached to a 
ubiquinol antioxidant, whereas SS-31 is a cell-permeable peptide with an 
antioxidant dimethyltyrosine residue specifically targeted to the inner 
mitochondrial membrane based on its alternating cationic aromatic residue 
sequence(15, 16, 87). It is expected that the myocardial I/R rat hearts treated 
with MitoQ or SS-31, given at reperfusion, will have greater preserved cardiac 
contractile function and smaller infarct size following myocardial I/R in 
comparison to the untreated I/R rat hearts. 
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METHODS 
Isolated Rat Heart Preparation 
 Male Sprague-Dawley rats (275-325 g, Charles River, Springfield, MA) 
were anesthetized intraperitoneally (i.p.) with pentobarbital sodium (60 mg/kg); 
the injection also contained sodium heparin (1,000 U). Each heart was rapidly 
excised and subjected to retrograde perfusion via the aorta with a modified 
Krebs-Henseleit buffer (in mmol/L: 17.0 dextrose, 120.0 NaCl, 25.0 NaHCO3, 2.5 
CaCl2, 0.5 EDTA, 5.9 KCl and 1.2 MgCl2). The perfusate was maintained at 
37 oC, kept at 80 mmHg constant pressure, aerated with 95% O2-5% CO2 and 
equilibrated at a pH of 7.35-7.45(88, 89).  
 The aorta of the isolated rat heart was cannulated onto a perfusion needle 
and immersed in a water-jacketed reservoir containing 160 mL of modified 
Krebs-Henseleit  buffer (Figure 7).  
Figure 7. The isolated perfused rat heart was 
cannulated via the aorta with a perfusion needle while 
immersed in a water-jacketed reservoir containing 
160 mL of modified Krebs-Henseleit  buffer. Also 
shown in this picture is the pressure transducer 
inserted into the left ventricular cavity to monitor 
cardiac function parameters.  
 
 
A flowmeter (T106, Transonic Systems, Inc., 
Ithaca, NY) was inserted into the perfusion line to 
monitor coronary flow.  Left ventricular end-
systolic pressure (LVESP), left ventricular end-
diastolic pressure (LVEDP), heart rate, and the peak rates of rise and fall in the 
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first derivative of left ventricular pressure (dP/dtmax and dP/dtmin, respectively) 
were monitored using a pressure transducer (SPR-524, Millar Instruments, Inc., 
Houston, TX) positioned in the left ventricular cavity and recorded using a 
Powerlab Station acquisition system (ADInstruments, Grand Junction, CO).  Left 
ventricular developed pressure (LVDP) was calculated by subtracting the LVEDP 
from the LVESP. Insertion of the pressure transducer catheter into the left 
ventricle allowed Krebs’ buffer to fill the left ventricle and establish preload 
volume. During the baseline period, the preload of the hearts of all study groups 
were be similar due to the limited weight range (275-325 g) of the animals as 
seen in previous studies(89-91). The initial baseline LVEDP was between 4-9 
mmHg for all hearts in each study group.  Coronary flow, LVESP, LVEDP, heart 
rate, dP/dtmax, and dP/dtmin were measured every 5 min for 15 min to ensure that 
stable baseline measurements were obtained. Figure 8 illustrates a schematic 
diagram of the I/R protocol in the isolated perfused rat heart.   
 
Figure 8. Myocardial I/R protocol. A 30 min perfusion period replaced ischemia in sham 
groups. At the beginning of the 45 min reperfusion period, 5 mL of autologous plasma ± 
MitoQ or SS-31 was infused 1 mL/min for 5 min. 
 
 Once a stable baseline was established, ischemia was induced for 30 min 
by quickly reducing the flow of Krebs’ buffer to zero. One of the three side arms 
in the perfusion line proximal to the heart inflow cannula was used for the 
infusion of 5 mL of autologous plasma (control hearts) or autologous plasma 
baseline 
stabilization 
15 min 
ischemia 
 
30 min 
reperfusion 
 
45 min 
TTC 
staining 
↑ ↑  ↑   
heart 
connected to 
I/R apparatus 
flow of modified 
Krebs-Henseleit 
buffer reduced to 0 
autologous plasma ± MitoQ or SS-31 
infusion 
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containing MitoQ (1, 10, 20 μM) or SS-31 (25, 50, 100 μM). After 30 min of 
ischemia, the flow of Krebs’ buffer was restored simultaneously with an infusion 
of either 5 mL of plasma (control I/R) or 5 mL of plasma containing MitoQ or SS-
31 at a rate of 1 mL/min for 5 min. Sham hearts were not subjected to ischemia 
and were given the 5 mL infusion of plasma at a rate of 1 mL/min for 5 min 
following 30 minutes of continuous perfusion in lieu of ischemia. Beginning at the 
infusion of plasma, cardiac function parameters were recorded every 5 min for 45 
min. 
 At the end of the experimental protocol, the right and left ventricles were 
separated from each heart. Three sections of the left ventricle were used for 
2,3,5- triphenyltetrazolium chloride (TTC) staining.  
Groups of Isolated Perfused Hearts 
The 9 groups of isolated perfused rat hearts used in the study are shown 
in Table 1.  Two types of control groups were used in the study based on 
previously established myocardial I/R models. Sham hearts were continuously 
perfused with the modified Krebs-Henseleit buffer for a 30 min period in lieu of 
the 30 min ischemia period and infused with 5 mL of plasma (1 mL/min) 
immediately following the 30 min perfusion period (i.e., the same time point that 
all I/R hearts would be given 5 mL of plasma). This group was utilized to show 
that cardiac function (i.e., LVDP, dP/dtmax, dP/dtmin, coronary flow,,  and heart 
rate) is maintained with no significant changes over a 90 min isolated perfused 
heart protocol, suggesting that any damage or cadiac dysfunction is due to injury 
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associated with ischemia and reperfusion. Control I/R hearts were subjected to a 
30 min period of ischemia followed by 45 min of reperfusion including an infusion 
of 5 mL of plasma (1 mL/min) in the first 5 min of reperfusion immediately 
following ischemia. This group was used to show the compromised 
postreperfused heart function after 30 min ischemia and 45 min reperfusion in 
the absence of any drugs compared to the baseline measurements of cardiac 
function. The drug treated I/R groups consist of I/R + MitoQ and I/R + SS-31 as 
shown in Table 1. 
 
Isolation of Plasma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Blood was collected in 1 mL of citrate phosphate dextrose buffer (Sigma 
Chemical Co., St. Louis, MO) from the abdominal aorta of the same rat from 
which the heart was isolated for each myocardial I/R experiment to simulate in 
vivo conditions. The blood was centrifuged at 10,000 x g for 10 min at 4 °C. The 
plasma was decanted from the blood, and 5 mL of the plasma collected from 
each rat was used for its corresponding isolated perfused heart during the 
infusion period at the beginning of reperfusion in all myocardial I/R groups.   
TTC Staining 
Once the 45 min reperfusion period was complete, the right ventricle was 
separated from the left ventricle and placed in liquid nitrogen. The apex and two 
Table 1. Isolated Perfused Rat Heart Treatment Groups 
 Control I/R MitoQ  SS-31  
  1 μM 10 μM 20 μM 25 μM 50 μM 100 μM 
Sham n=6       
I/R n=14 n=6 n=7 n=6 n=6 n=6 n=6 
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middle sections were isolated from the base of the left ventricle, and the base of 
the left ventricle was placed in liquid nitrogen. The apex and two middle sections 
were each placed in 1 mL of TTC for 15 min to visualize infarcted tissue areas. 
TTC is a salt that can be reduced by dehydrogenases to triphenylformazan, a fat 
soluble, light-sensitive compound which stains viable tissue bright red. Areas 
deficient in dehydrogenase activity remain the pale white color of the TTC salt. 
Previous studies have shown that the differentiation between viable and infarcted 
tissue by TTC staining correlates with loss of dehydrogenase activity and is 
therefore a reliable tool to measure infarct size(92-94). The weight ratio of 
infarcted cardiac tissue to the total area of tissue at risk was calculated and 
statistically analyzed.  
Statistical Analysis 
All data in the text and figures were presented as means ± SEM.  The 
cardiac function and TTC staining data were analyzed by ANOVA using post hoc 
analysis with the Student-Newman-Keuls test.  Probability values of <0.05 were 
considered to be statistically significant. 
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RESULTS 
I/R + MitoQ (1 μM, 10 μM, 20 μM) 
Cardiac Function 
 Sham hearts, which were not subjected to ischemia, are shown in all 
cardiac function graphs as reference points to illustrate the impact of I/R on 
cardiac function. Table 2 expresses the percent recovery, a comparison of the 
final to initial values, and Figures 9, 10, and 11 show the initial and final values of 
LVDP, dP/dtmax, and dP/dtmin from each experimental group, respectively.  
 
There was no statistically significant difference initially between the 
baseline values between any of the experimental groups. Additionally, there was 
no statistically significant difference between the initial and final values of LVDP, 
dP/dtmax, or dP/dtmin in the sham hearts. The sham hearts showed that there is 
not a significant decrease in cardiac function due to the experimental protocol in 
lieu of ischemia. In contrast, cardiac function of the control I/R hearts was 
significantly compromised by 45 min postreperfusion compared to baseline 
Table 2. Infarct Size (%) and LVDP, dP/dtmax, and dP/dtmax Percent Recovery 
 Control I/R MitoQ  SS-31  
  1 μM 10 μM 20 μM 25 μM 50 μM 100 μM 
Infarct 
Size 
45.0±2.1 53.9±6.3 26.7±3.2** 23.3±2.1** 25.2±3.8** 18.9±2.0** 20.6±1.9** 
LVDP 47.6±3.0 58.9±9.2 76.7±4.0* 69.5±7.8* 47.3±5.9 80.6±3.4** 62.1±6.4 
dP/dtmax 37.7±3.0 40.9±7.4 62.0±3.3* 55.2±5.4* 42.6±3.1 70.5±5.8** 49.0±2.6 
dP/dtmin 48.7±1.3 59.4±8.8 72.1±8.2 63.5±10.4 43.1±5.2 81.4±4.1* 61.7±7.9 
All data were analyzed using ANOVA with the Student Newman Keuls test (*p<0.05, 
**p<0.01 compared to control I/R) 
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cardiac function (P<0.01). At the end of each experiment, control I/R hearts 
recovered to 47.6 ± 3.0 % of initial LVDP, 37.7 ± 3.0 % of initial dP/dtmax, and 
48.7 ± 1.3 % dP/dtmin (Table 2, Figs. 9-11). I/R hearts treated with MitoQ (10, 20 
μM) significantly recovered in LVDP and  dP/dtmax (P<0.05 compared to control 
I/R; Table 2, Figs. 9 and 10); whereas lower dose (1 µM) MitoQ was not 
statistically different from the I/R control (Table 2, Figs. 9 and 10). Interestingly, 
even though MitoQ (10, 20 μM) was able to improve postreperfused dP/dtmax, 
there was not a significant difference in the postreperfused dP/dtmin between the 
MitoQ (10, 20 μM) treated I/R hearts and untreated I/R hearts (Table 2, Fig. 11). 
Overall, these results suggest that the infusion of MitoQ (10, 20 μM) at 
reperfusion improves postreperfused cardiac contractile function compared to I/R 
control hearts (P<0.05).  
Figure 9. Initial (before 
ischemia) and final (at 45 
min reperfusion) 
measurements from 
isolated perfused rat 
hearts of left ventricular 
developed pressure 
(LVDP), expressed in 
mmHg. (*P<0.05 
compared to control). All 
values are expressed as 
mean ± SEM. The number 
of hearts in each 
experimental group is 
shown in the box at the 
base of each bar. 
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Figure 10. Initial (before 
ischemia) and final (at 45 
min reperfusion) 
measurements from 
isolated perfused rat 
hearts of the peak rate of 
rise in the first derivative of 
left ventricular systolic 
pressure (dP/dtmax), 
expressed in mmHg/s. 
(*P<0.05 compared to 
control). All values are 
expressed as mean ± 
SEM. The number of 
hearts in each 
experimental group is 
shown in the box at the 
base of each bar. 
 
 
 
Figure 11. Initial (before 
ischemia) and final (at 
45 min reperfusion) 
measurements from 
isolated perfused rat 
hearts of the minimal 
rate of left ventricular 
systolic pressure in the 
first derivative (dP/dtmin), 
expressed in mmHg/s. 
(*P<0.05 compared to 
control). All values are 
expressed as mean ± 
SEM. The number of 
hearts in each 
experimental group is 
shown in the box at the 
base of each bar. 
 
 
 Moreover, the time courses of LVDP, dP/dtmax, and dP/dtmin show that the 
I/R control group exhibited sustained contractile dysfunction throughout the 45 
min period of reperfusion following ischemia compared to the sham hearts that 
did not experience ischemia (P<0.01). However, the I/R hearts treated with 10 
μM MitoQ showed significantly recovered LVDP by the 20 min time point and 
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significantly recovered dP/dtmax by the 30 min time point, suggesting that cardiac 
contractile function can recover more quickly after an infusion of MitoQ (10 μM) 
and sustain better contractile function by 45 min of reperfusion compared to 
untreated I/R controls (Figs. 12 and 13, both P<0.05). Additionally, I/R hearts 
treated with 20 μM MitoQ showed significant improvement in LVDP and dP/dtmax 
by 40 min reperfusion compared to untreated I/R controls (Figs. 12 and 13, both 
P<0.05). However, MitoQ (10, 20 μM) was not able to significantly restore 
dP/dtmin compared to untreated I/R control hearts (Fig. 14). The I/R hearts treated 
with a 1 μM dose of MitoQ did not show any significant changes in LVDP, 
dP/dtmax, or dP/dtmin throughout the I/R timecourse (Figs. 12-14).  
 
Figure 12. Time course of measurements of left ventricular developed pressure (LVDP) 
expressed in mmHg from initial baseline period (before ischemia) to the final recording 
time point (at 45 min reperfusion) from isolated perfused rat hearts (*P<0.05, **P<0.01 
compared to control I/R; †P<0.05 compared to MitoQ 20 µM). All values are expressed 
as mean ± SEM.  
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Figure 13. Time course of measurements of the peak rate of rise in the first derivative of 
left ventricular systolic pressure (dP/dtmax) expressed in mmHg/s from initial baseline 
period (before ischemia) to the final recording time point (at 45 min reperfusion) from 
isolated perfused rat hearts. (*P<0.05, **P<0.01 compared to control I/R; 
#P<0.05;†P<0.05 compared to MitoQ 20 µM). All values are expressed as mean ± SEM.  
 
 
Figure 14. Time course of measurements of the minimal rate of left ventricular systolic 
pressure in the first derivative (dP/dtmin) expressed in mmHg/s from initial baseline period 
(before ischemia) to the final recording time point (at 45 min reperfusion) from isolated 
perfused rat hearts. All values are expressed as mean ± SEM.  
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I/R + SS-31 (25 μM, 50 μM, 100 μM) 
Cardiac Function 
 Figures 15, 16, and 17 show the initial and final values of LVDP, dP/dtmax, 
and dP/dtmin from each experimental group, respectively. There was no 
statistically significant difference initially between the baseline values between 
any of the experimental groups. I/R hearts treated with SS-31 50 μM significantly 
recovered in LVDP, dP/dtmax, and dP/dtmin compared to untreated control I/R 
(P<0.01 compared to untreated control I/R, Table 2, Figs. 15-17); whereas SS-31 
(25, 100 µM) treatment did not show statistical difference from the untreated I/R 
control (Table 2, Figs. 15-17).  
Figure 15. Initial (before 
ischemia) and final (at 45 min 
reperfusion) measurements 
from isolated perfused rat 
hearts of left ventricular 
developed pressure (LVDP), 
expressed in mmHg. 
(**P<0.01 compared to 
control I/R). All values are 
expressed as mean ± SEM. 
The number of hearts in each 
experimental group is shown 
in the box at the base of each 
bar. 
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Figure 16. Initial (before 
ischemia) and final (at 45 
min reperfusion) 
measurements from isolated 
perfused rat hearts of the 
peak rate of rise in the first 
derivative of left ventricular 
systolic pressure (dP/dtmax), 
expressed in mmHg/s. 
(**P<0.01 compared to 
control I/R). All values are 
expressed as mean ± SEM. 
The number of hearts in 
each experimental group is 
shown in the box at the base 
of each bar. 
 
 
 
 
Figure 17. Initial (before 
ischemia) and final (at 45 
min reperfusion) 
measurements from 
isolated perfused rat 
hearts of the minimal rate 
of left ventricular systolic 
pressure in the first 
derivative (dP/dtmin) 
expressed in mmHg/s. 
(**P<0.01 compared to 
control I/R). All values 
are expressed as mean ± 
SEM. The number of 
hearts in each 
experimental group is 
shown in the box at the 
base of each bar. 
 
 
 Moreover, the time courses of LVDP, dP/dtmax, and dP/dtmin show that the 
I/R control group exhibited sustained contractile dysfunction throughout the 45 
min period of reperfusion following ischemia compared to the sham hearts that 
did not experience ischemia (P<0.01). However, the I/R hearts treated with 50 
μM SS-31 showed significantly recovered LVDP, dP/dtmax, and dP/dtmin by the 15 
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min time point, suggesting that cardiac contractile function can recover more 
quickly after an infusion of SS-31 (50 μM) and sustain better contractile function 
by 45 min of reperfusion compared to untreated I/R controls (Figs. 18-20, all 
P<0.01).  
 
Figure 18. Time course of measurements of left ventricular developed pressure (LVDP) 
expressed in mmHg from initial baseline period (before ischemia) to the final recording 
time point (at 45 min reperfusion) from isolated perfused rat hearts. Infusion of SS-31 at 
reperfusion attenuated cardiac contractile dysfunction by allowing LVDP to recover 
closer to baseline values throughout the time course of the experiment (**P<0.01 
compared to control I/R; #P<0.05, ##P<0.01 compared to SS-31 25 µM;†P<0.05 
compared to SS-31 100 µM). All values are expressed as mean ± SEM.  
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Figure 19. Time course of measurements of the peak rate of rise in the first derivative of 
left ventricular systolic pressure (dP/dtmax) expressed in mmHg/s from initial baseline 
period (before ischemia) to the final recording time point (at 45 min reperfusion) from 
isolated perfused rat hearts. Infusion of SS-31 at reperfusion attenuated cardiac 
contractile dysfunction by allowing dP/dtmax to recover closer to baseline values 
throughout the time course of the experiment (**P<0.01 compared to control I/R; 
#P<0.05, ##P<0.01 compared to SS-31 25 µM;†P<0.05,††P<0.01  compared to SS-31 100 
µM). All values are expressed as mean ± SEM. 
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Figure 20. Time course of measurements of the minimal rate of left ventricular systolic 
pressure in the first derivative (dP/dtmin) expressed in mmHg/s from initial baseline period 
(before ischemia) to the final recording time point (at 45 min reperfusion) from isolated 
perfused rat hearts. Infusion of SS-31 at reperfusion attenuated cardiac contractile 
dysfunction by allowing dP/dtmin to recover closer to baseline values throughout the time 
course of the experiment (*P<0.05, **P<0.01 compared to control I/R; #P<0.05, ##P<0.01 
compared to SS-31 25 µM;†P<0.05  compared to SS-31 100 µM)All values are 
expressed as mean ± SEM. 
 
 
I/R + MitoQ (1 μM, 10 μM, 20 μM) and I/R + SS-31 (25 μM, 50 μM, 100 μM) 
Infarct Size 
Figure 21 illustrates cross sections of left ventricular tissue stained with 
1% TTC to detect infarct size. 
Figure 21. Representative cross sections of I/R left ventricles subjected to TTC staining. 
Viable tissue stained red while the areas of infarction stained white. 
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The weight ratio of cardiac tissue infarct to the total area at risk was calculated 
and statistically analyzed. The I/R hearts treated with MitoQ (10 μM and 20 μM) 
or SS-31 (25, 50, 100 μM) showed a significantly smaller infarct size compared to 
untreated I/R controls (P<0.01 compared to control I/R; Table 2, Fig. 22). These 
results suggest that the infusion of MitoQ or SS-31 at reperfusion significantly 
reduces the amount of cardiac tissue death following I/R. However, the I/R hearts 
treated with 1 μM MitoQ did not show a significant difference in infarct size 
compared to untreated I/R hearts, suggesting that there is no cardioprotective 
effect at this dose (Fig. 22). 
 
Figure 22. Ratio of infarct size to total cardiac tissue at risk as determined by TTC 
staining. Infusion of MitoQ (10, 20 μM) or SS-31 (25, 50, 100 μM) at reperfusion 
attenuated cardiac tissue death compared to untreated I/R hearts (*P<0.05, **P<0.01). 
All values are expressed as mean ± SEM.  
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DISCUSSION 
Summary of major findings 
The results of this study suggest the infusion of MitoQ (10, 20 μM) at 
reperfusion improves postreperfused cardiac contractile function compared to I/R 
control hearts. The effect of MitoQ on cardiac function correlates with the infarct 
size data, suggesting the effects of the infusion of MitoQ at reperfusion can range 
from 1 to 20 μM. By contrast, all SS-31 treated I/R hearts showed a reduction in 
infarct size compared to the untreated control I/R hearts, but only the 50 μM dose 
of SS-31 elicited improvement in cardiac function within the 45 minute 
reperfusion period. This result is consistent with a previous myocardial I/R study 
in which a SS-31 analog (i.e., Bendavia) showed a reduction in infarct size but no 
significant improvement in cardiac function(95). Kloner et al. suggest SS peptides 
can reduce infarct size in I/R but may not improve post-reperfused cardiac 
function because the myocardium may be reversibly stunned and require more 
time to improve. Similarly, in this myocardial I/R study, SS-31 significantly 
reduced infarct size compared to the untreated control I/R hearts, yet the 25 and 
100 μM doses of SS-31 could not restore cardiac function within the 45 minute 
reperfusion period as quickly as the 50 μM dose of SS-31. Since it has been 
suggested that most I/R-induced damage occurs within the first 5 minutes of 
reperfusion, it is important to discover agents that can work rapidly and 
effectively to reduce the amount of I/R injury(8, 9). 
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These results suggest that mitochondrial ROS may be a significant 
contributor to myocardial I/R injury and are consistent with the hypothesis that 
inhibiting the release and accumulation of excess mitochondrial ROS with MitoQ 
or SS-31 attenuates myocardial I/R injury and subsequent cardiac contractile 
dysfunction and tissue death. 
The effects of MitoQ on cardiac contractile function and infarct size in I/R 
 The administration of MitoQ (10, 20 μM) at reperfusion significantly 
restored postreperfused LVDP and dP/dtmax closer to baseline levels and 
reduced infarct size in comparison to untreated I/R hearts. Although the 10 and 
20 μM doses of MitoQ significantly restored LVDP and dP/dtmax (P<0.05), none of 
the doses of MitoQ significantly restored postreperfused dP/dtmin in comparison to 
I/R controls. This finding suggests that postreperfused MitoQ treated hearts 
reach maximum contractility quickly but relax at a rate comparable to that of 
postreperfused untreated I/R hearts. MitoQ (10, 20 μM) administered at 
reperfusion was able to allow LVDP to recover more closely to baseline values 
after 45 min reperfusion than untreated I/R hearts. Although there was no 
significant difference in LVEDP between the experimental groups at the final time 
point in these experiments, lower post-I/R LVEDP could possibly contribute to the 
improved LVDP recovery in MitoQ-treated hearts. Although the I/R hearts treated 
with 20 μM of MitoQ reached final contractile function measurements similar to 
those of the I/R hearts treated with 10 μM, the time course of the I/R hearts 
treated with 20 μM showed that these hearts did not significantly differ from 
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untreated control I/R hearts in the 5-35 min period of reperfusion. In contrast, the 
I/R hearts treated with 10 μM of MitoQ significantly improved in LVDP by the 15 
min time point and in dP/dtmax by the 30 min time point. This delay in effect of the 
20 μM dose of MitoQ could possibly be attributed to reversible dysfunction in 
viable cells since these hearts significantly recovered LVDP and dP/dtmax by 45 
min reperfusion and also had a significantly smaller infarct size compared to 
untreated control I/R hearts. There was no statistical significance between MitoQ 
(1, 10, 20 μM) and untreated I/R hearts in the heart rate, coronary flow, LVESP, 
or LVEDP final values. While it would be expected that a decrease in infarct size 
would correlate with an increase in coronary flow, such an effect was not evident 
in this study(89, 95-97). In summary, postreperfused MitoQ-treated I/R hearts 
display significantly restored cardiac contractile function and smaller infarct size 
than untreated I/R hearts. These results suggest that mitochondrial ROS may be 
a significant contributor to myocardial I/R injury, and inhibiting the release of 
mitochondrial ROS with selective mitochondria-targeted antioxidants attenuates 
myocardial I/R injury and subsequent cardiac contractile dysfunction. 
 These results are consistent with the findings of other studies in which 
MitoQ attenuated tissue damage and dysfunction in I/R models. The Adlam et al. 
2005 study reported that a pretreatment of MitoQ (500μM) in drinking water given 
to rats for two weeks prior to I(30min)/R(60min) improved postreperfused cardiac 
function in isolated rat hearts compared to I/R control hearts. Specifically, MitoQ-
treated rat hearts achieved a significantly improved recovery of postreperfused 
LVDP in comparision to treatment with untargeted antioxidant compounds(16). A 
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similar study using pretreatment with MitoQ (500 μM) in drinking water for 10 
days prior to I(20min)/R(90min) in isolated perfused rat hearts showed an 
improvement in LVDP by 20% compared to I/R control hearts(74). The response 
to myocardial I/R of the MitoQ pretreated isolated perfused hearts in these 
studies suggests that mitochondria-derived ROS is a source of oxidative stress 
implicated in myocardial I/R injury. 
 The cardioprotective effects attributed to MitoQ were also investigated in 
another study in which rats were treated with doxorubicin (DOX), a drug known to 
induce cardiomyopathy, and MitoQ. These rats were treated for 12 weeks with 
DOX, MitoQ, or DOX plus MitoQ. Two-dimensional echocardiography measured 
the left ventricular function, which decreased in DOX-treated rats but was 
preserved during MitoQ plus DOX treatment. In addition, cytochrome c oxidase 
function was restored in DOX plus MitoQ (2 mg/kg) rats but diminished in DOX-
treated rats(98). The dose of MitoQ administered in the DOX-treated rat study is 
similar to the dose range used by our research group to show a reduction in rat 
blood H2O2 levels when administered during reperfusion compared to untreated 
I/R controls(99). In a hypertensive rat model of cardiovascular disease, MitoQ 
reduced cardiac dysfunction, blood pressure, cardiac hypertrophy, and 
endothelial dysfunction(100). Bovine aortic endothelial cells pretreated with 
MitoQ (1 µM) and incubated with glucose/glucose oxidase, to induce caspase 
activation, inhibited H2O2-induced apoptosis and lipid and protein peroxidation 
while also preserving mitochondrial membrane potential(101). Although 
pretreatment with MitoQ in these studies exhibited significant cardioprotective 
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effects, administering MitoQ as a pretreatment may not be a practical option in 
clinical occurrences of myocardial infarction. Therefore, administering MitoQ at 
reperfusion may prove more useful. MitoQ has exhibited protective effects when 
given during reperfusion following one hour ischemia in liver I/R and resulted in 
reduced ALT and AST liver enzymes immediately following ischemia and 
throughout a 24 hour reperfusion. Consequently, a smaller percentage of 
damaged liver tissue was found in the MitoQ treatment group(30). The 
concentration of MitoQ used in this liver I/R model was similar to the doses of 
MitoQ used in our in vivo hind limb I/R and ex vivo myocardial I/R models, which 
showed that MitoQ can reduce blood H2O2 levels and infarct size, respectively, in 
I/R(99, 102). Antioxidants that are targeted specifically to mitochondria, 
especially those that work rapidly and achieve efficacy when administered upon 
reperfusion, may be useful clinically in reducing mitochondrial oxidative damage 
following the reperfusion of ischemic tissue. 
The effects of SS-31 on cardiac contractile function and infarct size in I/R 
 SS-31 (50 μM, P<0.01) administered at reperfusion also significantly 
restored postreperfused cardiac contractile function parameters, LVDP, dP/dtmax, 
and dP/dtmin, significantly compared to untreated I/R hearts. There was no 
statistical significance between SS-31 (25, 50, 100 μM) and untreated I/R hearts 
in the heart rate, coronary flow, LVESP, or LVEDP final values. Administration of 
SS-31 (25, 50, 100 μM; P<0.01) at reperfusion significantly reduced infarct size 
compared to untreated I/R hearts. Unexpectedly, the administration of the 25 and 
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100 μM doses of SS-31 at reperfusion did not have significant restoration in 
cardiac function compared to untreated I/R hearts, but there was a significant 
decrease in infarct size in these I/R hearts (P<0.01). This anomaly could 
potentially be attributed to reversible I/R-induced myocardial stunning. Reversibly 
stunned myocardium is mechanically arrhythmic but could possibly regain 
function at a later time. Dysfunction in viable cells could potentially be reversed, 
whereas infarction is irreversible. Therefore, it is possible that cardiac function 
could improve or decline at a time point beyond the time course recorded in this 
study. This anomaly is consistent with the findings of a study investigating the 
cardioprotective effects of Bendavia, an analogue of SS-31 and SS-02, in 
myocardial I/R. The study found that treatment with Bendavia reduced infarct 
size in guinea pig and sheep myocardial I/R models. However, there was no 
effect on left ventricular output or arrhythmia score compared to untreated I/R 
animals. It has been suggested that the surviving myocardium surrounding an 
infarct may remain stunned for days to weeks following I/R(95). This explanation 
may account for why the 25 and 100 µM doses of SS-31 did not significantly 
improve post-reperfused cardiac function despite significantly decreasing infarct 
size compared to untreated I/R controls(102). The results of the present study 
suggest that mitochondrial ROS may be a significant contributor to myocardial 
I/R injury, and inhibiting the release of mitochondrial ROS with selective 
mitochondria-targeted antioxidants attenuates myocardial I/R injury and may 
have a beneficial effect on subsequent cardiac contractile dysfunction. 
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The efficacy of SS-31 has been attributed to its ability to become 
selectively concentrated within mitochondria to scavenge ROS, whereas SS-20 
is targeted to mitochondria but unable to scavenge ROS because lacks a Dmt 
amino acid residue(18, 26, 103). Administration as a pretreatment followed by a 
second treatment at reperfusion with SS-31 (i.p.), similar in dosage to the SS-31 
that reduced blood H2O2 in an in vivo hind limb I/R model, was able to 
significantly reduce infarct size, ventricular arrhythmias, and lipid peroxidation in 
a rat myocardial I(60min)/R(60min) model in vivo(75, 99). A study using an ex 
vivo guinea pig global myocardial I(30min)/R(90) model showed SS-31 is able to 
prevent myocardial stunning when given throughout the experiment effectively, 
and these results were later obtained with an SS-31 analog using an in vivo 
myocardial I/R model(8, 73, 82, 104). The results from this study are unique in 
that SS-31 was administered exclusively at reperfusion and still able to improve 
infarct size and post-reperfused cardiac function; administration at the time of 
reperfusion may be more clinically relevant in cases of patients experiencing 
myocardial infarction(102). These results suggest that mitochondrial-derived 
ROS is a significant contributing factor to myocardial stunning, and reduction in 
mitochondrial ROS is cardioprotective. Similarly, SS-31 (2 mg/kg, i.p.) 
administered at reperfusion in a mouse cerebral I(30min)/R(72h) model 
significantly reduced infarct size compared to the untreated I/R brains(87, 105). 
The activity of tert-butyl hydroperoxide, known to induce mitochondrial 
depolarization and apoptosis by lipid peroxidation, was reduced in neuronal cell 
lines also treated with SS-31. SS-31 also exhibited ROS-scavenging activity in 
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the same neuronal cell lines(26). A subcuteaneous pretreatment, treatment at 
reperfusion, and post treatment with SS-31 in a rat kidney I(30-45min)/R(24h) 
model resulted in preserved mitochondrial structure and function as well as 
reduced oxidative stress and inflammation following I/R(18). In hepatocytes 
treated with hypochlorous acid, SS-31 was able to prevent cell death by inhibiting 
an increase in mitochondrial SO and mitochondrial depolarization(106). SS-31 
was also able to prevent an increase in mitochondrial SO due to induced shear 
stress in endothelial cells(107). SS-31 has also been effective in a chronic model 
of cardiac dysfunction by alleviating hypertensive cardiomyopathy. In the study, 
SS-31 was able to significantly reduce angiotensin II-induced mitochondrial 
oxidative stress, apoptosis signaling, and fibrosis(22). Furthermore, SS-31 is also 
able to promote the activity of mitochondrial respiration and synthesis of ATP in 
addition to its ability to scavenge ROS and attenuate ROS production and 
mitochondrial swelling(108, 109). 
Future Studies 
 To more clearly understand the role of mitochondrial-derived ROS in 
contributing to myocardial I/R injury, direct measurements of mitochondrial ROS 
at various I/R time points may allow clarification of the correlation between the 
amount of ROS release and tissue damage in myocardial I/R. These types of 
measurements may also quantify the efficacy of selectively mitochondrial-
targeted antioxidants in reducing mitochondrial ROS release. In a similar way, 
infarct size could be measured at more than one time point to confirm the ratio of 
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tissue death that occurs during the reperfusion phase to the ischemic phase of 
I/R. To supplement the infarct size data, histological staining for apoptosis 
markers may be useful to confirm areas of cell death. No sham hearts in this 
study were given SS-31 treatment, which may be a useful way to confirm 
whether or not SS-31 itself alters cardiac function independently from I/R. Other 
selectively mitochondrial-targeted antioxidants may also be used in a similar 
myocardial I/R model. Additionally, eNOS uncoupling has been shown to 
contribute to I/R injury by initiating endothelial dysfunction and increased ROS 
release within 5-10 min of reperfusion(52, 53). Measurements of the eNOS dimer 
to monomer ratio via western blotting of left ventricular tissue or high 
performance liquid chromatography to detect the BH4 to BH2 ratio may be useful 
in monitoring the degree of eNOS activity in myocardial I/R and understanding 
the relationship between endothelial dysfunction and myocardial I/R injury.  
 For more effective translation into the clinical setting, the cardioprotective 
effects of agents given at reperfusion need to be reproducible in multiple 
laboratories, models, and species. One of the limitations of the isolated perfused 
heart model is that there is a limited time course. Measurements of infarct size 
and cardiac function at time points 24 hours or longer may be better predictors of 
morbidity and mortality following acute myocardial infarction. I/R-induced 
myocardial stunning may mask the potential function of postreperfused cardiac 
tissue since stunning can be reversible. An in vivo regional I/R model could also 
be used to confirm the results of a global ischemia model and obtain 
measurements at later time points. Most studies of myocardial I/R use healthy, 
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juvenile animals without comorbid conditions or varying nutritional or hormonal 
status(5). Comorbid conditions, such as diabetes, hypertension, 
hypercholesterolemia, and left ventricular hypertrophy, are commonly found in 
the clinical setting and may impact the efficacy of cardioprotective 
interventions(5, 110, 111). Patients in the clinical setting may also have been 
exposed to transient periods of angina with a preconditioning effect, which can 
skew the interpretation of how much of the cardioprotective effect can be 
contributed to an intervention(5).  
Significance of Findings 
 Selectively mitochondrial-targeted antioxidants administered at the time of 
reperfusion in myocardial I/R exerted cardioprotective effects in this study. MitoQ 
and SS-31 infused with autologous plasma at the beginning of reperfusion both, 
independently, expeditiously and effectively restored postreperfused cardiac 
contractile function and reduced infarct size. The results of this study suggest 
that MitoQ and SS-31 may effectively reduce I/R injury during the treatment of 
myocardial infarction or heart transplantation in the clinical setting, thus allowing 
these patients to have a better quality of life attributable to better cardiac function 
and more viable cardiac tissue following ischemic events.  
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